Thrilled to announce that Lyell Immunopharma entered into a definitive agreement to acquire ImmPACT Bio! The combination will bring together a world-class Team and a pipeline of next-generation CAR T-cell therapies. Our first clinical data readout from IMPT-314’s ongoing Phase 1/2 study will be presented at a major medical conference later this year. “I am incredibly proud of the ImmPACT team and all of their accomplishments in developing next-generation CAR T-cell therapies,” stated Sumant Ramachandra, M.D., Ph.D., Chief Executive Officer of ImmPACT. “This transaction validates our novel science and enhances the potential for this therapy to make a meaningful impact on patients' lives. I am confident that in Lyell, we have found a team that shares our passion for advancing novel science to benefit patients.” Thank you to our employees, leadership team, collaborators, scientific and clinical partners, Founders, investors, Board of Directors, and many more people for the support as we built ImmPACT Bio from its academic roots to a company with several open INDs, ongoing clinical programs and a robust pipeline of next-generation CAR T-cell therapies. Read more here: https://lnkd.in/gy2dT-ta #CARTCellTherapy #NextGenerationTherapies #Biotechnology #MakeAnImmPACT
ImmPACT Bio
Biotechnology Research
West Hills, California 7,957 followers
We are developing advanced therapies for cancer patients with critical unmet needs
About us
ImmPACT Bio USA, Inc., is a clinical-stage company dedicated to the discovery of transformative chimeric antigen receptor (CAR) T-cell therapies that address key biological challenges in treating cancer and autoimmune diseases. Our technology is designed to precisely distinguish cancer and diseased cells from normal cells; thereby eliminating them without damaging normal tissues. The company was founded in 2017 in the FuturRx incubator (Israel). In 2019, ImmPACT Bio was incorporated in the US. In 2021 ImmPACT Bio merged with Kalthera. In 2022 we moved our Corporate offices to West Hills, CA and built a state-of-the-art clinical manufacturing facility.
- Website
-
immpactbio.com
External link for ImmPACT Bio
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- West Hills, California
- Type
- Privately Held
- Founded
- 2017
- Specialties
- CAR-T, Immunotherapy, Cancer Therapy, On target off tumor toxicity , Selective treatment , Logic gate, Oncology, Biotechnology, Research, Immunotherapy, autoimmune, and lupus
Locations
-
Primary
8501 Fallbrook Ave
200
West Hills, California 91304, US
-
2 E.D.Bergman St.
Rehovot, IL
Employees at ImmPACT Bio
-
Ofir Goldberger 🧪
Biotech Corporate / Business Development and Licensing
-
Sheila Gujrathi, MD
Biotech Executive | Physician Scientist | Healthcare Investor | Drug Developer | TEDx Speaker
-
Carolyn Gabus
Senior Director, Clinical Operations at ImmPACT Bio
-
Sumant Ramachandra, M.D., Ph.D.
CEO & Board Director at ImmPACT Bio
Updates
-
Welcome to the ImmPACT Bio team, Jesus Salas! #welcometotheteam, #cartcelltherapy, #MakeAnImmPACT
-
We stand with the fighters, celebrate the survivors, and honor the memory of those we've lost to this disease. Together, we raise awareness and push forward in the fight against breast cancer. Early detection and continued innovation in treatments make all the difference. Let’s keep working towards a future where breast cancer is a thing of the past. #BreastCancerAwareness #TogetherWeFight #ImmPACTBio
-
Welcome to the ImmPACT Bio team, Jenny Gong! #welcometotheteam, #CARTcelltherapy, #MakeAnImmPACT
-
ImmPACT Bio is pleased to announce that we will participate at the 2024 Cell and Gene Meeting on the Mesa, to be held October 7-9, 2024 in Phoenix, AZ. #cartcelltherapy, #CGMesa24, #MakeAnImmPACT
-
On this September 11, we pause to honor the memory of those we lost and express our gratitude to the heroes who emerged in the face of unimaginable tragedy. It's a reminder of the resilience, unity, and compassion that can arise in the darkest of times. #NeverForget #September11 #Resilience
-
Welcome to the ImmPACT Bio team, Marcia Friedman, M.D.! #welcometotheteam, #cartcelltherapy, #MakeAnImmPACT
-
ImmPACT Bio is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted IND clearance for IMPT-514, a bispecific CAR T therapy, as a potential treatment of adult patients with #multiplesclerosis (MS). This dual CD19 and CD20-targeting CAR T therapy offers broad immune targeting and the potential to reset the immune system. Read the press release: https://bit.ly/3YRCr1q #CARTcelltherapy, #celltherapy, #autoimmunedisease
-
Welcome to the ImmPACT Bio team, Amanda Squires! #Welcometotheteam, #CARTcelltherapy, #MakeAnImmPACT